Evidências farmacológicas sobre plantas medicinais usadas para o tratamento de artrite reumatoide e osteoartrite (artrose)

Prof. Leopoldo Clemente Baratto
OrcID
Srª Katharine Augusto da Silva Monteiro
OrcID
Srª Beatriz Prata Pereira
OrcID

    Prof. Leopoldo Clemente Baratto

    Universidade Federal do Rio de Janeiro

    OrcID https://orcid.org/0000-0002-7125-7431

    Presidente da Sociedade Brasileira de Farmacognosia (SBFgnosia) na gestão 2017-2019. Professor Adjunto da Universidade Federal do Rio de Janeiro-UFRJ, Faculdade de Farmácia, Departamento de Produtos Naturais e Alimentos-DPNA. De agosto de 2014 a dezembro de 2015 foi Professor Adjunto da Universidade Federal do Oeste do Pará-UFOPA, Instituto de Saúde Coletiva, Curso de Farmácia, no Campus de Santarém-PA. Possui graduação em Farmácia pela Universidade Federal de Santa Catarina (UFSC) e os títulos de Mestre (2010) e Doutor (2013) em Ciências Farmacêuticas pela Universidade Federal do Paraná (UFPR). De abril de 2012 a março de 2013 desenvolveu estágio doutoral no exterior (período sanduíche), na Martin-Luther-Universität em Halle (Saale)-Alemanha, no grupo de pesquisa do Prof. Dr. Reinhard Paschke. Atua nas áreas de Farmácia e Química de Produtos Naturais, com ênfase nos seguintes tópicos: isolamento e elucidação estrutural de produtos naturais, principalmente alcaloides indólicos e triterpenos; morfoanatomia vegetal; desenvolvimento e validação de métodos analíticos para quantificação de analitos em matérias-primas vegetais; biotransformação de moléculas orgânicas usando micro-organismos e células vegetais; modificação estrutural de protótipos naturais (semissíntese); e avaliação de atividades biológicas in vitro (atividades antitumoral, antimalárica, antimicrobiana e anti-HIV).

    Srª Katharine Augusto da Silva Monteiro

    Universidade Federal do Rio de Janeiro

    OrcID https://orcid.org/0009-0009-7305-5639

    Graduanda em farmácia pela Universidade Federal do Rio de Janeiro.

    Srª Beatriz Prata Pereira

    Universidade Federal do Rio de Janeiro

    OrcID https://orcid.org/0009-0003-1617-5315

    Cursando Farmácia pela Universidade Federal do Rio de Janeiro (UFRJ). Técnica em Automação Industrial com o ensino médio completo pelo CEFET/RJ Campus Maria da Graça.

Palavras-chave

Harpagophytum procumbens
Hypericum perforatum
Miconia albicans
Uncaria tomentosa
Varronia curassavica

Resumo

A artrite reumatoide (AR) e a osteoartrite (OA) são enfermidades de grande impacto social que acarretam fortes dores, deformidades e incapacidade para atividades rotineiras e laborais. No Brasil, mesmo com as Políticas Nacionais de Práticas Integrativas e Complementares (PNPIC) e de Plantas Medicinais e Fitoterápicos (PNPMF) que permitiram ampliar o acesso à Fitoterapia, continua muito comum a difusão sobre o uso de plantas medicinais de maneira equivocada, muitas vezes sem nenhuma evidência científica de eficácia. O objetivo deste trabalho foi selecionar algumas plantas popularmente indicadas na internet para uso em tratamento de AR e OA e buscar dados de eficácia e segurança, sendo elas Harpagophytum procumbens, Hypericum perforatum, Miconia albicans, Uncaria tomentosa e Varronia curassavica. A partir de uma revisão da literatura englobando ensaios in vitro, pré-clínicos e clínicos foram encontrados resultados promissores sobre a ação dessas plantas sobre AR e OA. A maioria dos trabalhos reforça os efeitos anti-inflamatório, antiartrítico e analgésico dessas espécies, porém, como os mecanismos ainda não são elucidados, mais estudos são necessários, principalmente clínicos, para se chegar a uma melhor conclusão. Essa revisão bibliográfica poderá contribuir e alertar profissionais da saúde e pacientes que buscam esses produtos para tratamento de doenças reumáticas.

Referências

  1. Pereira D, Ramos E, Branco J. Osteoarthritis. Acta Méd Portug. 2015; 28(1): 99-106. [https://doi.org/10.20344/amp.5477].
  2. Myers SP, O'Connor J, Fitton JH, Brooks L, Rolfe M, Connellan P. A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis. Biol Targets Ther. 2010; 4: 33-44. [https://doi.org/10.2147/btt.s8354].
  3. Coimbra IB, Pastor EH, Greve JMD, Puccinelli MLC, Fuller R, Cavalcanti FS. Osteoartrite (artrose): tratamento. Rev Bras Reumatol. 2004; 44(6): 450-3. Disponível em: [https://www.scielo.br/j/rbr/a/F39LTRWZ985dPVQTpYPcvfJ].
  4. Farpour HR, Rajabi N, Ebrahimi B. The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: a randomized active-controlled clinical trial. Evidence-Based Compl Alter Medic. 2021; 2021: 5596892. [https://doi.org/10.1155/2021/5596892].
  5. Rosis RG, Massabki OS, Kairalla M. Osteoartrite: avaliação clínica e epidemiológica de pacientes idosos em instituição de longa permanência. Rev Soc Bras Clín Méd. 2010; 8(2): 101-108. Disponível em:[http://files.bvs.br/upload/S/1679-1010/2010/v8n2/a003.pdf].
  6. Rezende MU, Campos GC, Pailo AF. Conceitos atuais em osteoartrite. Acta Ortop Bras. 2013; 21(2): 120-2. [https://doi.org/10.1590/S1413-78522013000200010].
  7. Brasil. Comissão de Osteoartrite da Sociedade Brasileira de Reumatologia. Osteoartrite (Artrose) – Cartilha para pacientes. Sociedade Brasileira de Reumatologia. 2011. Disponível em: [http://www.dol.inf.br/Html/CartilhaOsteoartrite/CartilhaOsteoartrite.pdf].
  8. Sartori-Cintra AR, Aikawa P, Cintra DEC. Obesidade versus osteoartrite: muito além da sobrecarga mecânica. Einstein (São Paulo). 2014; 12(3): 374-9. [https://doi.org/10.1590/S1679-45082014RB2912].
  9. Rezende MU, Campos GC, Pailo AF. Conceitos atuais em osteoartrite. Acta Ortop Bras. 2013; 21(2): 120-2. [https://doi.org/10.1590/S1413-78522013000200010].
  10. Holtmann H, Resch K. Cytokines. Naturwissenschaften. 1995; 82(4): 178-87. [https://doi.org/10.1007/BF01143192].
  11. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arth Care Res. 2020; 72(2): 149-62. [https://doi.org/10.1002/acr.24131].
  12. Christensen R, Astrup A, Bliddal H. Weight loss: the treatment of choice for knee osteoarthritis? a randomized trial. Osteoarth Cartilage. 2005; 13(1): 20-7. [https://doi.org/10.1016/j.joca.2004.10.008].
  13. Negrini S, Donzelli S, Lusini M, Minnella S, Zaina F. The effectiveness of combined bracing and exercise in adolescent idiopathic scoliosis based on SRS and SOSORT criteria: a prospective study. BMC Musculoskel Disorders. 2014; 15: 263. [https://doi.org/10.1186/1471-2474-15-263].
  14. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the eular standing committee for international clinical studies including therapeutics (ESCISIT). Annals Rheumatic Dis. 2005; 64(5): 669-81. [https://doi.org/10.1136/ard.2004.028886].
  15. Brasil. Sociedade Brasileira de Reumatologia-SBR. 2022. Osteoartrite (Artrose). Disponível em: [https://www.reumatologia.org.br/doencas/principais-doencas/osteoartrite-artrose/].
  16. Jin X, Yan E, Wang H, Sui H, Liu Z, Gao W et al. Hyperoside exerts anti-inflammatory and anti-arthritic effects in LPS-stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis. Acta Pharmacol Sinica. 2016; 37(5): 674-86. [https://doi.org/10.1038/aps.2016.7].
  17. Kapoor M, Pelletier JM, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2010; 7(1): 33-42. [https://doi.org/10.1038/nrrheum.2010.196].
  18. Maione F, Russo R, Khan H, Mascolo N. Plantas Medicinais com atividades anti-inflamatórias. Nat Prod Res. 2015; 30(12): 1343-1352. [https://doi.org/10.1080/14786419.2015.1062761].
  19. Yatoo MI, Gopalakrishnan A, Saxena A, Parray OR, Tufani NA, Chakraborty S et al. Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review. Recent Pat Inflamm Allergy Drug Discov. 2018; 12(1): 39-58. [https://doi.org/10.2174/1872213X12666180115153635].
  20. Nunes CDR, Arantes MB, Pereira SMF, Cruz LL, Passos MS, Moraes LP, Vieira IJC, Oliveira DB. Plants as Sources of Anti-Inflammatory Agents. Molecules. 2020; 25(16): 3726. [https://doi.org/10.3390/molecules25163726].
  21. De Smet PAGM. Health risks of herbal remedies: an update. Clin Pharmacol Therap. 2004; 76(1): 1-17. [https://doi.org/10.1016/j.clpt.2004.03.005].
  22. Van-Rooyen RM, Pretorius B, Tembani NM, Ham-Baloyi W. Evidence-based recommendations to facilitate professional collaboration between allopathic and traditional health practitioners. Health SA Gesondheid. 2017; 22(1): 291-299. [https://doi.org/10.1016/j.hsag.2017.05.001].
  23. Medeiros RD, Bezerra AS, De Oliveira RB, De Lima JBF, Da Silva LV, Oliveira G et al. Uso seguro e racional de produtos naturais e fitoterápicos: a utilização das redes sociais digitais para interação entre profissionais da área da saúde e a sociedade. Rev Ext Soc. 2020; 11(2). [https://doi.org/10.21680/2178-6054].
  24. Gilbert B, Favoreto R. Cordia verbenacea DC. Boraginaceae. Monografia. Rev Fitos. jan-mar. 2012; 7(1): 17-25. [https://pesquisa.bvsalud.org/portal/resource/pt/far-2012].
  25. Sertié JAA, Basile AC, Panizza S, Matida AK, Zelnik R. Anti-inflammatory activity and Sub-Acute Toxicity of Artemetin. Pl Méd. 1990; 56(1): 36-40. [https://doi.org/10.1055/s-2006-960879].
  26. Ventrella MC, Marinho CR. Morphology and histochemistry of glandular trichomes of Cordia verbenacea DC. (Boraginaceae) leaves. Rev Bras Bot. 2008; 31(3): 457-467. [https://doi.org/10.1590/S0100-84042008000300010].
  27. Silva Junior AA, Vizzotto VJ, Giorgi E; Macedo SG, Marques LF. Plantas medicinais, caracterização e cultivo. EPAGRI-Itajaí, 71p. Boletim Técnico, 68. 1995. [ISSN: 7416].
  28. Brasil. Agência Nacional de Vigilância Sanitária-ANVISA. Formulário de Fitoterápicos da Farmacopeia Brasileira, 2ª edição. Brasília: ANVISA 2021. Disponível em: [https://www.gov.br/anvisa/pt-br/assuntos/farmacopeia/formulario-fitoterapico/2023-fffb2-1-er-2-atual-final-versao-com-capa-em-word-25-abr-2023.pdf].
  29. ACHE. Bula Acheflan Cordia verbenacea DC. Creme – 5mg. Disponível em: [https://www.ache.com.br/arquivos/BU_ACHEFLAN-CREME_ACHE_JUL2012.pdf].
  30. Dutra RC, Campos MM, Santos ARS, Calixto JB. Medicinal plants in Brazil: pharmacological studies, drug discovery, challenges and perspectives. Pharmacological Research. 2016; 112: 4-29. [https://doi.org/10.1016/j.phrs.2016.01.021].
  31. Sertié JA, Basile AC, Panizza S, Matida AK, Zelnik R. Pharmacological Assay of Cordia verbenacea; Part 1. Anti-Inflammatory Activity and Toxicity of the Crude Extract of the Leaves. Planta Medica. 1988; 54(1): 7-10. [https://doi.org/10.1055/s-2006-962318].
  32. Sertié JA, Basile AC, Panizza S, Oshiro TT, Azzolini CP, Penna SC. Pharmacological assay of Cordia verbenacea III: Oral and topical anti-inflammatory activity and gastrotoxicity of a crude leaf extract. J Ethnopharmacol. 1991; 31(2): 239-47. [https://doi.org/10.1016/0378-8741(91)90008-2].
  33. Sertié JAA, Woisky RG, Wiezel G, Rodrigues M. Pharmacological assay of Cordia verbenacea V: oral and topical anti-inflammatory activity, analgesic effect and fetus toxicity of a crude leaf extract. Phytomedicine. 2005; 12(5): 338-44. [https://doi.org/10.1016/j.phymed.2003.09.013]
  34. Refsio C, Brandão DC, Brandão GC, Korukian M, Garcia RJ, Bonfiglioli R et al. Clinical assessment of efficacy and safety from Cordia verbenacea standardized extract in tendinits and chronical miofacial pain patients. Rev Bras Medic. 2005; 62(1-2): 40-46.
  35. Stochla K, Maśliński S. Carrageenan-induced oedema in the rat paw-histamine participation. Agents Actions. 1982; 12(1-2): 201-2. [https://doi.org/10.1007/BF01965145].
  36. Hwang SB, Lam MH, Li CL, Shen TY. Release of platelet activation factor and its involvement in the first phase of carrageenin-induced rat foot edema. Europ J Pharmacol. 1986; 120(1): 33-41. [https://doi.org/10.1016/0014-2999(86)90636-9].
  37. Gilligan JP, Lovato SJ, Erion MD, Jeng AY. Modulation of carrageenan-induced hind paw edema by substance P. Inflammation. 1994; 18(3): 285-92. [https://doi.org/10.1007/BF01534269].
  38. De Campos RO, Alves RV, Kyle DJ, Chakravarty S, Mavunkel BJ, Calixto JB. Antioedematogenic and antinociceptive actions of NPC 18521, a novel bradykinin B2 receptor antagonist. Europ J Pharmacol. 1996; 316(2-3): 277-86. [https://doi.org/10.1016/s0014-2999(96)00661-9].
  39. Passos GF, Fernandes ES, Cunha FM, Ferreira J, Pianowski LF, Campos MM et al. Anti-inflammatory and anti-allergic properties of the essential oil and active compounds from Cordia verbenacea. J Ethnopharmacol. 2007; 110 (2): 323-33. [https://doi.org/10.1016/j.jep.2006.09.032].
  40. Van-Assche G, Rutgeerts P. Anti-TNF agents in Crohn’s disease. Exp Opinion Investig Drugs. 2000; 9: 103–111. [https://doi.org/10.1517/13543784.9.1.103].
  41. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002; 2(5): 364-71. [https://doi.org/10.1038/nri802].
  42. Fernandes ES, Passos GF, Medeiros R, Cunha FM, Ferreira J, Campos MM et al. Anti-inflammatory effects of compounds alpha-humulene and (−)-trans-caryophyllene isolated from the essential oil of Cordia verbenacea. Europ J Pharmacol. 2007; 569(3): 228-36. [https://doi.org/10.1016/j.ejphar.2007.04.059].
  43. Bodini RB, Pugine SMP, Melo MP, Carvalho RA. Antioxidant and anti-inflammatory properties of orally disintegrating films based on starch and hydroxypropyl methylcellulose incorporated with Cordia verbenacea (erva baleeira) extract. Inter J Biol Macromolec. 2020; 159:714-24. [https://doi.org/10.1016/j.ijbiomac.2020.05.075].
  44. Basting RT, Spindola HM, Sousa IMO, Queiroz NCA, Trigo JR, JE Carvalho et al. Pterodon pubescens and Cordia verbenacea association promotes a synergistic response in antinociceptive model and improves the anti-inflammatory results in animal models. Biomed Pharmacother. 2019; 112: 108693. [https://doi.org/10.1016/j.biopha.2019.108693].
  45. Mills S, Bone K. Principles and Practice of Phytotherapy: Modern Herbal Medicine. Churchill Livingdtone, Edinburg, 439-447. Harcourt Publishers Ltd.: Londres. 2000.
  46. Wegener T. Devil's Claw: from African traditional remedy to modern analgesic and anti-inflammatory. Herbal Gram. 2000;(50): 47-54. Disponivel em: [https://www.herbalgram.org/resources/herbalgram/issues/50/table-of-contents/article2285/].
  47. Tyler VE. The Honest Herb.: A sensible guide to the use of herbs and related remedies. 3a ed. New York: Pharmaceutical Products, 1993.
  48. Baghdikian B, Lanhers MC, Fleurentin J, Ollivier E, Maillard C, Balansard G, Mortier F et al. An Analytical Study and Anti-Inflammatory and Analgesic Effects of Harpagophytum procumbens and Harpagophytum zeyheri. Pl Med. 1997; 63(2): 171-6. [https://doi.org/10.1055/s-2006-957638].
  49. Mncwangi N, Chen W, Vermaak I, Viljoen AM, Gericke N. Devil’s Claw - a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbens. J Ethnopharmacol. 2012; 143(3): 755-71. [https://doi.org/10.1016/j.jep.2012.08.013].
  50. Apsen Farmacêutica S/A. Bula Apardol - Harpagophytum procumbens DC. Cápsulas – 20 mg harpagosídeo. Disponível em: [https://www.apsen.com.br/bula/Arpadol/Bula-Arpadol-Profissional.pdf].
  51. Natulab Laboratório S.A. Bula Arpynflan Harpagophytum procumbens. Comprimidos revestidos – 18 mg harpagosídeo. Disponível em: [https://natulab.com.br/wp-content/uploads/2019/10/Arpynflan-Bula_Paciente-1.pdf].
  52. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Relação Nacional de Medicamentos Essenciais - RENAME. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Brasília - DF, 2022. 1ª edição. Disponível em: [https://www.gov.br/saude/pt-br/composicao/sectics/daf/rename/20210367-rename-2022_final.pdf].
  53. Belaiche P. Etude clinique de 360 cas d’arthrose traités par le nébulisat aqueux d’Harpagophytum procumbens. Phytotherapie. 1982; 1:22–28.
  54. Chrubasik S, Künzel O, Thanner J, Conradt C, Black A. A 1-year follow-up after a pilot study with Doloteffin® for low back pain. Phytomedicine. 2005; 12(1-2): 1-9. [https://doi.org/10.1016/j.phymed.2004.01.005].
  55. Conrozier T, Mathieu P, Bonjean M, Marc JF, Renevier JL, Balblanc JC. A complex of three natural anti-inflammatory agents provides relief of osteoarthritis pain. Alter Ther Health Medic. 2014; 20(1): 32-7. [PMID: 24473984].
  56. Lim DW, Kim JG, Han D, Kim YT. Analgesic Effect of Harpagophytum procumbens on Postoperative and Neuropathic Pain in Rats. Molecules. 2014; 19(1): 1060-8. [https://doi.org/10.3390/molecules19011060].
  57. Park KS. A Systematic Review on Anti-Inflammatory Activity of Harpagoside. J Biochem Molec Biol Res. 2016; 2(3): 166-9. Disponível em: [http://www.ghrnet.org/index.php/jbmbr/article/view/1715].
  58. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom. 2004; 18(19): 2273-81. [https://doi.org/10.1002/rcm.1621].
  59. Ernst E. Herbal medicines: where is the evidence? British Med J. 2000; 321(7258): 395-6. [https://doi.org/10.1136/bmj.321.7258.395].
  60. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. Churchill Livingstone, Edinburgh, pp. 234. 816p. 2003. ISBN-13:‎ 978-0443071454.
  61. Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine. 2000; 7(3): 177-83. [https://doi.org/10.1016/S0944-7113(00)80001-X].
  62. Lanhers MC, Fleurentin J, Mortier F, Vinche A, Younos C. Anti-inflammatory and analgesic effects of an aqueous extract of Harpagophytum procumbens. Planta Medica; 1992; 58(2): 117-23. [https://doi.org/10.1055/s-2006-961411]
  63. Mahomed IM, Ojewole JAO. Analgesic, anti-inflammatory and antidiabetic properties of Harpagophytum procumbens DC (Pedaliaceae) secondary root aqueous extract. Phytother Res. 2005; 18(12): 982-9. [https://doi.org/10.1002/ptr.1593]
  64. Anauate MCC, Torres LMB, Mello SBV. Uso dos fitoterápicos, Harpagophytum procumbens (garra-do-diabo) e Uncaria tomentosa (unha-de-gato) no tratamento da osteoartrite de coluna lombar. 2009. Art Hypertexto. Disponível em: [http://www.infobibos.com/Artigos/2009_4/fitoterapicos/index.htm]
  65. Haseeb A, Ansari MY, Haqqi TM. Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes. J Orthop Res. 2017; 35(2): 311-320. [https://doi.org/10.1002/jor.23262]
  66. Ghasemian M, Owlia S, Owlia MB. Review of Anti-Inflammatory Herbal Medicines. Adv Pharmacol Sci. 2016; 2016: 9130979. [https://doi.org/10.1155/2016/9130979].
  67. Inaba K, Murata K, Naruto S, Matsuda H. Inhibitory effects of devil’s claw (secondary root of Harpagophytum procumbens) extract and harpagoside on cytokine production in mouse macrophages. J Nat Medic. 2010; 64(2): 219-22. [https://doi.org/10.1007/s11418-010-0395-8].
  68. Schopohl P, Grüneberg P, Melzig MF. The influence of harpagoside and harpagide on TNFα-secretion and cell adhesion molecule mRNA-expression in IFNγ/LPS-stimulated THP-1 cells. Fitoterapia. 2016; 110: 157-65. [https://doi.org/10.1016/j.fitote.2016.03.005].
  69. Chung HJ, Kim WK, Park HJ, Cho L, Kim MR, Kim MJ et al. Anti-osteoporotic activity of harpagide by regulation of bone formation in osteoblast cell culture and ovariectomy-induced bone loss mouse models. J Ethnopharmacol. 2016; 179: 66-75. [https://doi.org/10.1016/j.jep.2015.12.025].
  70. Rahimi A, Razmkhah K, Mehrnia M, Mohamadnia A, Sahebjamee H, Salehi S et al. Molecular docking and binding study of harpagoside and harpagide as novel anti-inflammatory and anti-analgesic compound from Harpagophytum procumbens based on their interactions with COX-2 enzyme. Asian Pacif J Trop Dis. 2016; 6(3): 227-31. [https://doi.org/10.1016/S2222-1808(15)61019-2].
  71. Mariano A, Sotto AD, Leopizzi M, Garzoli S, Maio VD, Gullì M et al. Antiarthritic effects of a root extract from Harpagophytum procumbens DC: novel insights into the molecular mechanisms and possible bioactive phytochemicals. Nutrients. 2020; 12(9): 2545. [https://doi.org/10.3390/nu12092545].
  72. Zhang L, Feng L, Jia Q, Xu J, Wang R, Wang Z et al. Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. Bioorg Medic Chem. 2011; 19(16): 4882-6. [https://doi.org/10.1016/j.bmc.2011.06.069].
  73. Farpour HR, Rajabi N, Ebrahimi B. The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: a randomized active-controlled clinical trial. Evidence-Based Compl Alter Medic. 2021; 2021: 5596892. [https://doi.org/10.1155/2021/5596892].
  74. Huang THW, Tran VH, Duke RK, Tan S, Chrubasik S, Roufogalis BD et al. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-κB activation. J Ethnopharmacol. 2006; 104(1-2): 149-55. [https://doi.org/10.1016/j.j].
  75. Andersen ML, Santos EHR, Seabra MLV, Silva AAB, Tufik S. Evaluation of acute and chronic treatments with Harpagophytum procumbens on Freund’s adjuvant-induced arthritis in rats. J Ethnopharmacol. 2004; 91(2-3): 325-30. [https://doi.org/10.1016/j.jep.2004.01.003]
  76. Chrubasik S, Thanner J, Künzel O, Conradt C, Black A, Pollak S. Comparison of out come measures during treatment with the proprietary Harpagophytum extract Doloteffin® in patients with pain in the lower back, knee or hip. Phytomedicine. 2002; 9(3): 181-94. [https://doi.org/10.1078/0944-7113-00140]
  77. Chrubasik S, Chrubasik C, Künzel O, Black A. Patient-perceived benefit during one year of treatment with Doloteffin®. Phytomedicine. 2007; 14(6): 371-6. [https://doi.org/10.1016/j.phymed.2007.04.011].
  78. Gyurkovska V, Alipieva K, Maciuk A, Dimitrova P, Ivanovska N, Haas C et al. Anti-inflammatory activity of Devil’s claw in vitro systems and their active constituents. Food Chem. [S.L.]. 2011; 125(1): 171-178. [https://doi.org/10.1016/j.foodchem.2010.08.056].
  79. Jang MH, Lim S, Han SM, Park HJ, Shin I, Kim JW et al. Harpagophytum procumbens Suppresses Lipopolysaccharide-Stimulated Expressions of Cyclooxygenase-2 and Inducible Nitric Oxide Synthase in Fibroblast Cell Line L929. J Pharmacol Sci. 2003; 93(3): 367-71. [https://doi.org/10.1254/jphs.93.367].
  80. Kaszkin M, Beck KF, Koch E, Erdelmeier C, Kusch S, Pfeilschifter J, Loew D. Downregulation of iNOS expression in rat mesangial cells by special extracts of Harpagophytum procumbens derives from harpagoside-dependent and independent effects. Phytomedicine. 2004; 11(7-8): 585-95. [https://doi.org/10.1016/j.phymed.2004.02.003].
  81. Kim TK, Park KS. Inhibitory effects of harpagoside on TNF-α-induced pro-inflammatory adipokine expression through PPAR-γ activation in 3T3-L1 adipocytes. Cytokine. 2015; 76(2): 368-374. [https://doi.org/10.1016/j.cyto.2015.05.015].
  82. Ouitas NA, Heard CM. A novel ex vivo skin model for the assessment of the potential transcutaneous anti-inflammatory effect of topically applied Harpagophytum procumbens extract. Inter J Pharmac. 2009; 376 (1-2): 63-8. [https://doi.org/10.1016/j.ijpharm.2009.04.017].
  83. Warnock M, McBean D, Suter A, Tan J, Whittaker P. Effectiveness and safety of Devil's Claw tablets in patients with general rheumatic disorders. Phytother Res. 2007; 21(12): 1228-33. [https://doi.org/10.1002/ptr.2288].
  84. Wegener T, Lüpke NP. Treatment of patients with arthrosis of hip or knee with an aqueous extract of Devil's Claw (Harpagophytum procumbens DC.). Phytother Res. 2003; 17(10): 1165-72. [https://doi.org/10.1002/ptr.1322].
  85. Al-Asmari KA, Al-Elaiwi MA, Athar MT, Tariq M, Al Eid A, Al-Asmary SM. A review of hepatoprotective plants used in Saudi Traditional Medicine. Evidence-Based Compl Alter Medic. 2014; 2014: 890842. [https://doi.org/10.1155/2014/890842].
  86. Meral GE, Karabay NU. In vitro antibacterial activities of three Hypericum species from West Anatolia. Turkish Electr J Biotechnol. 2002: 6–10. [Disponível em: [https://www.maltawildplants.com/CLUS/Docs/HYPTQ/Antimicrobialproperties.pdf].
  87. Mašković PZ, Mladenović JD, Cvijović MS, Đoković GA, Solujić SR, Radojković MM. Phenolic content, antioxidant and antifungal activities of acetonic, ethanolic and petroleum ether extracts of Hypericum perforatum L. Hemijska industrija, 2011; 65(2): 159-164. [https://doi.org/10.2298/HEMIND100819004M].
  88. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochr Database System Rev. 2008; 2008(4): CD000448. [https://doi.org/10.1002/14651858.CD000448.pub3].
  89. Stojanović G, Ðorđević A, Šmelcerović A. Do Other Hypericum Species Have Medical Potential As St. John’s Wort (Hypericum perforatum)?. Current Medic Chem. 2013; 20(18): 2273-95. [https://doi.org/10.2174/0929867311320180001].
  90. Kubin A, Wierrani F, Burner U, Alth G, Grünberger W. Hypericin-the facts about a controversial agent. Current Pharmac Design. 2005; 11(2): 233-53. [https://doi.org/10.2174/1381612053382287].
  91. Wong A, Townley SA. Herbal medicines and anaesthesia. Contin Educ Anaesthesia Critic Care Pain. 2011; 11(1): 14-17. [https://doi.org/10.1093/bjaceaccp/mkq046].
  92. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. British J Clin Pharmacol. 2002; 54(4): 349-56. [https://doi.org/10.1046/j.1365-2125.2002.01683.x].
  93. Šavikin K, Dobrić S, Tadić V, Zdunić G. Anti-inflammatory activity of ethanol extracts of Hypericum perforatum L., H. barbatum Jacq., H. hirsutum L., H. richeri Vill. and H. androsaemum L. in rats. Phytother Res. 2007; 21(2): 176-180. [https://doi.org/https://doi.org/10.1002/ptr.2041].
  94. Baeuerle PA, Henkel T. Function and Activation of NF-kappaB in the Immune System. Annual Rev Immunol. 1994; 12: 141-79. [https://doi.org/10.1146/annurev.iy.12.040194.001041].
  95. Hunt EJ, Lester CE, Lester EA, Tackett RL. Effect of St. John's wort on free radical production. Life Sci. 2001; 69(2): 181-90. [https://doi.org/10.1016/s0024-3205(01)01102-x].
  96. Silva BA, Ferreres F, Malva JO, Dias ACP. Phytochemical and antioxidant characterization of Hypericum perforatum alcoholic extracts. Food Chemistry. 2005; 90(1-2): 157-67. [https://doi.org/10.1016/j.foodchem.2004.03.049].
  97. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem. 1992; 267(36): 25934-8. [https://doi.org/10.1016/S0021-9258(18)35698-9].
  98. Nussler AK, Billiar TR. Inflammation, immunoregulation, and inducible nitric oxide synthase. J Leukocyte Biol. 1993; 54(2): 171-8. [PMID: 7689630].
  99. Raso GM, Meli R, Di Carlo G, Pacilio M, Di Carlo R. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci. 2001; 68(8): 921-31. [https://doi.org/10.1016/s0024-3205(00)00999-1].
  100. Abdel-Salam OME. Anti-inflammatory, antinociceptive, and gastric effects of Hypericum perforatum in rats. Scient World J. 2005; 5: 586-95. [https://doi.org/10.1100/tsw.2005.78].
  101. Tedeschi E, Menegazzi M, Margotto D, Suzuki H, Förstermann U, Kleinert H. Anti-inflammatory actions of St. John's wort: inhibition of human inducible nitric-oxide syntahse expression by down-regulating signal transducer and activator of transcription-1α (STAT-1α) activation. J Pharmacol Experim Ther. 307: 2003; 307(1): 254-61. [https://doi.org/10.1124/jpet.103.054460].
  102. Raso GM, Pacilio M, Di Carlo G, Esposito E, Pinto L, Meli R. In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum. J Pharm Pharmacol. 2002; 54(10): 1379-83. [https://doi.org/10.1211/002235702760345464].
  103. Kumar V, Singh PN, Bhattacharya SK. Anti-stress activity of Indian Hypericum perforatum L. Indian J Exper Biol. 2001; 39(4): 344-9. [PMID: 11491579].
  104. Sun K, Luo J, Jing X, Xiang W, Guo J, Yao X et al. Hyperoside ameliorates the progression of osteoarthritis: an in vitro and in vivo study. Phytomedicine. 2021; 80:153387. [https://doi.org/10.1016/j.phymed.2020.153387].
  105. Hatanaka J, Shinme Y, Kuriyama K, Uchida A, Kou K, Uchida S et al. In vitro and in vivo Characterization of New Formulations of (St. John's Wort) Extract with Improved Pharmacokinetics and Anti-nociceptive Effect. Drug Metab Pharmacok. Sep. 2011; 26(6): 551-8. [https://doi.org/10.2133/dmpk.DMPK-11-RG-041].
  106. Huang N, Rizshsky L, Hauck CC, Nikolau BJ, Murphy PA, Birt DF. The inhibition of lipopolysaccharide-induced macrophage inflammation by 4 compounds in Hypericum perforatum extract is partially dependent on the activation of SOCS3. Phytochemistry. 2012; 76:106-16. [https://doi.org/10.1016/j.phytochem.2011.12.001].
  107. Jang SA, Park DW, Sohn EH, Lee SR, Kang SC. Hyperoside suppresses tumor necrosis factor α-mediated vascular inflammatory responses by downregulating mitogen-activated protein kinases and nuclear factor-κB signaling. Chem Biol Interact. 2018; 294: 48-55. [https://doi.org/10.1016/j.cbi.2018.08.013].
  108. Arjona FBS, Montezuma RCM, Silva IM. Aspectos etnobotânicos e biogeografia de espécies medicinais e / ou rituais comercializados no mercado de Madureira, RJ. Caminhos Geogr. 2007; 8(23): 41–50. Disponível em: [https://seer.ufu.br/index.php/caminhosdegeografia/article/view/15661].
  109. Allenspach N, Dias MM. Frugivory by birds on Miconia albicans (Melastomataceae), in a fragment of cerrado. in São Carlos, southeastern Brazil. Braz J Biol. 2012; 72(2): 407-13. [https://doi.org/10.1590/s1519-69842012000200024].
  110. Reis C, Bieras AC, Sajo MG. Anatomia foliar de Melastomataceae do cerrado do Estado de São Paulo. Rev Bras Botân. 2005; 28(3): 451-466. [https://doi.org/10.1590/S0100-84042005000300004].
  111. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária-ANVISA. RDC Nº 400, de 16 de fevereiro de 2017. Disponível em: [https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2017/cha-canela-de-velho-interditado-por-nao-ter-registro].
  112. Greenhalgh L. Canela-de-velho: uma perspectiva sobre a venda irregular de plantas medicinais. 2020. Disponível em: [https://www.plantaciencia.com/colunas/canela-de-velho%3A-uma-perspectiva-sobre-a-venda-irregular-de-plantas-medicinais].
  113. Pieroni LG, Rezende FM, Ximenes VF, Dokkedal AL. Antioxidant activity and total phenols from the methanolic extract of Miconia albicans (Sw.) Trianaleaves. Molecules. 2011; 16(11): 9439–9450. [https://doi.org/10.3390/molecules16119439].
  114. Vasconcelos MAL, Royo VA, Ferreira DS, Crotti AEM, Silva MLA, Carvalho JCT et al. In vivo analgesic and anti-Inflammatory activities of ursolic acid and oleanoic acid from Miconia albicans (Melastomataceae). Zeitschrift für Naturforschung C A. J Biosci. 2006; 61(7-8): 477-82. [https://doi.org/10.1515/znc-2006-7-803].
  115. Moreira L. Avaliação da atividade tóxica em Artemia salina leach. de extratos de duas espécies da família melastomataceae. Anápolis, 2013. 43f. Trabalho de Conclusão de curso. [Graduação em Química] - Secretaria de Educação Profissional e Tecnológica, Instituto Federal de Educação, Ciência e Tecnologia de Goiás. Anápolis, GO. 2013.
  116. Shen XX, Hittinger CT, Rokas A. Contentious relationships in phylogenomic studies can be driven by a handful of genes. Nat Ecol Evol. 2017; 1(5): 0126. [https://doi.org/10.1038/s41559-017-0126].
  117. Serpeloni JM, Vilegas W, Varanda EA, Cólus IMS. Avaliação in vivo da anticlastogenicidade de extratos de plantas medicinais do gênero Miconia através do teste do micronúcleo. Semina: Ciênc Biol Saúde. 2008; 29(1): 47-56. [https://doi.org/10.5433/1679-0367.2008v29n1p47].
  118. Quintans-Júnior LJ, Gandhi SR, Passos FRS, Heimfarth L, Pereira EWM, Monteiro BS, et al. Dereplication and quantification of the ethanol extract of Miconia albicans (Melastomaceae) by HPLC-DAD-ESI-/MS/MS, and assessment of its anti-hyperalgesic and anti-inflammatory profiles in a mice arthritis-like model: evidence for involvement of tnf-α, il-1β and il-6. J Ethnopharmacol. 2020; 258: 112938. [https://doi.org/10.1016/j.jep.2020.112938].
  119. Gomes TPO, Souza JIN, Somerlate LC, Mendonça VA, Lima NM, Carli GP et al. Miconia albicans and Curcuma longa herbal medicines positively modulate joint pain, function and inflammation in patients with osteoarthritis: a clinical study. Inflammopharmacol. 2021; 29(2): 377-391. [https://doi.org/10.1007/s10787-020-00781-9].
  120. Corrêa JGS, Bianchina M, Lopes AP, Silva E, Ames FQ, Pomini AM et al. Chemical profile, antioxidant and anti-inflammatory properties of Miconia albicans (Sw.) Triana (Melastomataceae) fruits extract. J Ethnopharmacol. 2021; 273: 113979. [https://doi.org/10.1016/j.jep.2021.113979].
  121. Lima TC, Matos SS, Carvalho TF, Silveira-Filho AJ, Couto LPSM, Quintans-Júnior LJ et al. Evidence for the involvement of IL-1β and TNF-α in anti-inflammatory effect and antioxidative stress profile of the standardized dried extract from Miconia albicans Sw. (Triana) Leaves (Melastomataceae). J Ethnopharmacol. 2020; 259: 112908. [https://doi.org/10.1016/j.jep.2020.112908].
  122. Steyemark JA. Rubiaceae. In: Laser T. Flora de Venezuela. Caracas, Ve: Instituto Botánico, Dirección de Recursos Naturales Renovables, Ministerio de Agricultura y Cria, Caracas, v.9. p.1-2070. 1974.
  123. Gentry A. A field guide to the families and genera of woody plants of northwest South America. Conservation Internacional. Washington, DC. 1993.411p.
  124. Boom B, Delprete P. Uncaria: Plants central French Guiana. Brittonia, 1994; 46(2): 105-125.
  125. Rea RL. Cinchona y la tribu Cinchonaeae (Rubiaceae) en Bolivia, actualización sistemática, fitoquímica y actividad antimalárica, 183p. Bolivia, 1995. Tese (Graduação). Universidade Mayor de San Andrés de La Paz.
  126. Zevallos PP, Lombardi I, Bernal Y. Agrotecnología para el cultivo de la uña de gato o bejuco de agua”. In: Martínez JV, Bernal HJ, Cáceres A. In: Fundamentos de agrotecnología para el cultivo de plantas medicinais Iberoamericanas. Santafé de Bogotá, Colombia. Convenio Andrés Bello/Ciencia y Tecnología para el Desarrollo. p463- 492. 2000.
  127. Sandoval M, Okuhama NN, Zhang XJ, Condezo LA, Lao J, Angeles FM, et al. Anti-inflammatory and antioxidant activities of cat’s claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine. 2002; 9(4): 325-337. [ https://doi.org/10.1078/0944-7113-00117 ]
  128. Pereira RCA, Lopes JVM. Aspectos Botânicos, Etnobotânicos, Agronômicos e Fitoquímicos de Unha-de-Gato. Fortaleza: Embrapa Agroindústria Tropical, 2006. [Disponível em: [https://www.embrapa.br/busca-de-publicacoes/-/publicacao/1092500/aspectos-botanicos-etnobotanicos-agronomicos-e-fitoquimicos-de-unha-de-gato].
  129. Laus G. Advances in chemistry and bioactivity of the genus Uncaria. Phytother Res. 2004; 18(4): 259-74. [https://doi.org/10.1002/ptr.1469].
  130. Heitzman ME, Neto CC, Winiarz E, Vaisberg AJ, Hammond GB. Ethnobotany, phytochemistry and pharmacology of Uncaria (Rubiaceae). Phytochemistry. 2005; 66(1): 5-29. [https://doi.org/10.1016/j.phytochem.2004.10.022].
  131. Zhang Q, Zhao JJ, Xu J, Feng F, Qu W. Medicinal uses, phytochemistry and pharmacology of the genus Uncaria. J Ethnopharmacol. 2015; 173:48-80. [https://doi.org/10.1016/j.jep.2015.06.011].
  132. Peñaloza EMC, Kaiser S, Resende PE, Pittol V, Carvalho AR, Ortega GG. Chemical composition variability in the Uncaria tomentosa (cat's claw) wild population. Quím Nova. 2015; 38(3). [https://doi.org/https://doi.org/10.5935/0100-4042.20150007].
  133. Rojas-Duran R, González-Aspajo G, Ruiz-Martel C, Bourdy G, Doroteo-Ortega VH, Alban-Castillo J et al. Anti-inflammatory activity of Mitraphylline isolated from Uncaria tomentosa bark. J Ethnopharmacol. 2012; 143(3): 801-4. [https://doi.org/10.1016/j.jep.2012.07.015].
  134. Sandoval-Chacón M, Thompson JH, Zhang XJ, Liu X, Mannick EE, Sadowska-Krowicka H et al. Anti-inflammatory actions of cat’s claw: the role of NF-κb. Aliment Pharmacol Therap. 1998; 12(12): 1279-89. [https://doi.org/10.1046/j.1365-2036.1998.00424.x].
  135. Aguilar JL, Rojas P, Marcelo A, Plaza A, Bauer R, Reininger E et al. Anti-inflammatory activity of two different extracts of Uncaria tomentosa (Rubiaceae). J Ethnopharmacol. 2002; 81 (2): 271-6. [https://doi.org/10.1016/s0378-8741(02)00093-4].
  136. La Paz SM, Arche AF, Puerta R, Quilez AM, Muriana FJG, Gimenez MDG et al. Mitraphylline inhibits lipopolysaccharide-mediated activation of primary human neutrophils. Phytomedicine. 2016; 23(2): 141-8. [https://doi.org/10.1016/j.phymed.2015.12.015]
  137. Snow AD, Castillo GM, Nguyen BP, Choi PY, Cummings JA, Cam J et al. The Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. Scient Rep. 2019; 9: 561. [https://doi.org/10.1038/s41598-019-38645-0].
  138. Allen-Hall L, Cano P, Arnason JT, Rojas R, Lock O, Lafrenie RM. Treatment of THP-1 cells with Uncaria tomentosa extracts differentially regulates the expression if IL-1β and TNF-α. J Ethnopharmacol. 2007; 109(2):312-7. [https://doi.org/10.1016/j.jep.2006.07.039].
  139. Allen-Hall L, Arnason JT, Cano P, Lafrenie RM. Uncaria tomentosa acts as a potent TNF-α inhibitor through NF-κB. J Ethnopharmacol. 2010; 127(3): 685-93. [https://doi.org/10.1016/j.jep.2009.12.004].
  140. Castilhos LG, Rezer JFP, Ruchel JB, Thorstenberg ML, Jaques JAS, Schlemmer JB et al. Effect of Uncaria tomentosa extract on purinergic enzyme activities in lymphocytes of rats submitted to experimental adjuvant arthritis model. BMC Compl Alter Medic. 2015; 15(1): 189. [https://doi.org/10.1186/s12906-015-0694-4]. ISSN: 2662-7671
  141. Mur E, Hartig F, Eibl G, Schirmer M. Randomized double-blind trial of an extract from the pentacyclic alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. J Rheumatol. 2002; 29(4): 678-81. [PMID: 11950006].
  142. Azevedo BC, Morel LJF, Carmona F, Cunha TM, Contini SHT, Delprete PG et al. Aqueous extracts from Uncaria tomentosa (Willd. ex Schult.) DC. reduce bronchial hyperresponsiveness and inflammation in a murine model of asthma. J Ethnopharmacol. 2018; 218: 76-89. [https://doi.org/10.1016/j.jep.2018.02.013].
  143. Jürgensen S, DalBó S, Angers P, Santos ARS, Valle RMR. Involvement of 5-HT receptors in the antinociceptive effect of Uncaria tomentosa. Pharmacol Biochem Behav. 2005; 81(3): 466-77. [https://doi.org/10.1016/j.pbb.2005.04.004].

Artigos mais lidos pelo mesmo(s) autor(es)

PDF
HTML
Salvar em favoritos

Autor(es)

Métricas

  • Artigo visto 89 vez(es)

Como Citar

1.
Evidências farmacológicas sobre plantas medicinais usadas para o tratamento de artrite reumatoide e osteoartrite (artrose). Rev Fitos [Internet]. 2º de julho de 2024 [citado 7º de outubro de 2024];18:e1635. Disponível em: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1635
Crossref
Scopus
Google Scholar
Europe PMC
Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 Revista Fitos

Informe um erro